GB Sciences（GBLX）株式概要植物由来の研究およびバイオ医薬品開発企業であるGBサイエンシズ社。 詳細GBLX ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きいマイナスの株主資本 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( $106K )+2 さらなるリスクすべてのリスクチェックを見るGBLX Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.000417.6% 割高 内在価値ディスカウントEst. Revenue$PastFuture-26m4m2016201920222025202620282031Revenue US$97.2kEarnings US$14.2kAdvancedSet Fair ValueView all narrativesGB Sciences, Inc. 競合他社EcofibreSymbol: OTCPK:EOFB.FMarket cap: US$366.6kResonate BlendsSymbol: OTCPK:KOANMarket cap: US$382.2kSybleuSymbol: OTCPK:SYBEMarket cap: US$583.7kSofgen PharmaSymbol: OTCPK:PROC.FMarket cap: US$698.2k価格と性能株価の高値、安値、推移の概要GB Sciences過去の株価現在の株価US$0.000452週高値US$0.5052週安値US$0.000001ベータ10.711ヶ月の変化33.33%3ヶ月変化33.33%1年変化100.00%3年間の変化-97.24%5年間の変化-99.15%IPOからの変化-99.90%最新ニュースお知らせ • Nov 20GB Sciences, Inc. announced delayed 10-Q filingOn 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 13GB Sciences, Inc. announced delayed 10-Q filingOn 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15GB Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Nov 20GB Sciences, Inc. announced delayed 10-Q filingOn 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 13GB Sciences, Inc. announced delayed 10-Q filingOn 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15GB Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 12Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of LethbridgeGb Sciences, Inc. has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model. In addition to the dosage range findings, this study demonstrated that Gb Sciences' Parkinson's disease formulations were well tolerated, and there were no adverse effects. As early as next year, Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials. As the second most common neurodegenerative disease, the market for Parkinson's disease (PD) treatments is expected to grow to $12.8 billion by 2028. The dose response study in rodents performed at the University of Lethbridge helps to establish the correct dosing of Gb Sciences' cannabinoid-containing Parkinson's formulations for a first-in-human trial. Dr. Robert Sutherland, Ph.D., FRSC, Professor and Chair of the Department of Neuroscience at the University of Lethbridge, Board of Governors Research Chair in Neuroscience, and Director of the Canadian Centre for Behavioral Neuroscience, used deep learning models to analyze the rich data sets from their "Home Cage Small World" behavioral assessments of rodents with video cameras and Artificial Intelligence, using a system developed by Neurocage Systems Ltd. Future studies confirming the mechanism of action of these cannabinoid-based Parkinson's formulations are planned with Dr. Sutherland's research group at the University of Lethbridge using their behavioral measurement methods for rodents.お知らせ • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 20GB Sciences, Inc., Annual General Meeting, Mar 09, 2023GB Sciences, Inc., Annual General Meeting, Mar 09, 2023, at 10:00 Pacific Standard Time. Agenda: To consider and elect three directors to serve on Board of Directors and until each of their successors has been duly elected and qualified, unless such individuals shall sooner die, resign or be removed; to approve an amendment to articles of incorporation to increase the number of shares of stock Board of Directors is authorized to issue from 600,000,000 shares to 950,000,000 shares; to ratify the appointment of Assurance Dimensions as independent registered public accounting firm for the fiscal year ended March 31, 2023; and to transact such other business as may properly come before the Meeting or any postponement or adjournment thereof.お知らせ • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2022, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 30Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research ArticleGb Sciences, Inc. announced that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the University of Seville in Spain have developed time-released, oral nanoparticles to deliver Gb Sciences' patent-protected chronic pain formulations, which are based on synergistic mixtures of terpenes. Terpenes are normally highly volatile, highly lipophilic molecules that are difficult to formulate into stable drug products, so Gb Sciences and their colleagues believe that nanocarriers can improve their stability, solubility, and bioavailability. In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. Concerns over those issues have made novel chronic pain treatments such as Gb Sciences' therapies an important and promising field of research and development. The Gb Sciences-sponsored study tested the effect of poly(lactide-co-glycolide) nanoparticles containing the three terpenes versus the effect of free terpenes in a cell model with TRPV1 receptors, which are known pain receptors. The study found that the encapsulated terpene nanoparticles produced significantly higher calcium responses alone or in combinations versus the free terpenes alone or in combinations. The elevated calcium responses through the TRPV1 channels indicate greater activation of these pain receptors, which can have an analgesic effect via desensitization of these important pain receptors.お知らせ • Mar 03GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary CystitisGb Sciences, Inc. has been issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of TRPV1-receptor-associated hearing loss and urinary cystitis. Despite multiple categories of prescription heart medications on the market, heart disease remains the leading cause of death in the United States for people of most racial and ethnic groups. Alternative therapeutic approaches are still needed, especially for the treatment of advanced heart disease.お知らせ • Jan 13An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million.An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million on December 31, 2021. The sale, valued at $8 million, will allow Gb Sciences to reduce outstanding debt and bolster its cash position. The proceeds from this sale include $1.2 million in cash, $3.8 million in immediate debt and liabilities reduction, and a $3 million interest-bearing note payable to Gb Sciences by the buyer over a three-year term. An unknown buyer completed the acquisition of Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) on December 31, 2021.お知らせ • Sep 15GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related HyperinflammationGb Sciences, Inc. received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key anti-viral immune responses. Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August 18, 2021. The best-performing cannabinoid-containing complex mixtures will be further developed in preparation for clinical studies to evaluate their anti-inflammatory potential in the treatment of severely ill COVID-19 patients contending with Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions, such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS). CRS, MAS, and ARDS are the leading causes of death in COVID-19 patients.お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2021, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 26GB Sciences, Inc. Announces Resignation of Leslie Bocskor as A Member of the Board of DirectorsGB Sciences, Inc. announced that effective November 23, 2020, Mr. Leslie Bocskor resigned his position as a member of the board of directors of the Company to pursue other business interests.お知らせ • Sep 19Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX).Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017. GB Sciences did not receive any consideration in the transaction but was relieved of any obligation to fund the losses of GB Sciences Puerto Rico going forward. As the result of the transaction, GB Sciences deconsolidated the assets, liabilities and noncontrolling interests of GB Sciences Puerto Rico since its ownership interest was reduced to a non-controlling level. Cesar Cordero-Kruger completed the acquisition of an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017.お知らせ • Aug 18GB Sciences, Inc. announced delayed 10-Q filingOn 08/17/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 14GB Sciences, Inc. announced delayed annual 10-K filingOn 08/13/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.株主還元GBLXUS PharmaceuticalsUS 市場7D100.0%-1.5%2.6%1Y100.0%30.4%26.2%株主還元を見る業界別リターン: GBLX過去 1 年間で30.4 % の収益を上げたUS Pharmaceuticals業界を上回りました。リターン対市場: GBLX過去 1 年間で26.2 % の収益を上げたUS市場を上回りました。価格変動Is GBLX's price volatile compared to industry and market?GBLX volatilityGBLX Average Weekly Movement176.3%Pharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.1%10% least volatile stocks in US Market3.2%安定した株価: GBLXの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: GBLXの 週次ボラティリティ は過去 1 年間で2886%から176%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aAndrea Small-Howardwww.gbsciences.com植物由来の研究とバイオ医薬品開発を行うGBサイエンシズ社。同社は、大麻からヒントを得た医薬品や複雑な治療用混合物を処方薬市場向けに提供している。同社の知的財産は、パーキンソン病、神経障害性疼痛、慢性疼痛、サイトカイン放出症候群、ストレス／不安／うつ病、心血管治療プログラムなど、さまざまな病状と前臨床動物段階のプログラムをカバーしている。同社は以前はGrowblox Sciences, Inc.として知られていたが、2016年10月にGB Sciences, Inc.に社名を変更した。GBサイエンシズ社はネバダ州ラスベガスを拠点としている。もっと見るGB Sciences, Inc. 基礎のまとめGB Sciences の収益と売上を時価総額と比較するとどうか。GBLX 基礎統計学時価総額US$105.88k収益（TTM）-US$1.06m売上高(TTM)US$97.24k2.2xP/Sレシオ-0.2xPER（株価収益率GBLX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計GBLX 損益計算書（TTM）収益US$97.24k売上原価US$0売上総利益US$97.24kその他の費用US$1.15m収益-US$1.06m直近の収益報告Dec 31, 2024次回決算日該当なし一株当たり利益（EPS）-0.002グロス・マージン100.00%純利益率-1,085.52%有利子負債／自己資本比率-33.9%GBLX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 07:11終値2026/05/11 00:00収益2024/12/31年間収益2024/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GB Sciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 20GB Sciences, Inc. announced delayed 10-Q filingOn 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 13GB Sciences, Inc. announced delayed 10-Q filingOn 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15GB Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 20GB Sciences, Inc. announced delayed 10-Q filingOn 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 13GB Sciences, Inc. announced delayed 10-Q filingOn 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15GB Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 12Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of LethbridgeGb Sciences, Inc. has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model. In addition to the dosage range findings, this study demonstrated that Gb Sciences' Parkinson's disease formulations were well tolerated, and there were no adverse effects. As early as next year, Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials. As the second most common neurodegenerative disease, the market for Parkinson's disease (PD) treatments is expected to grow to $12.8 billion by 2028. The dose response study in rodents performed at the University of Lethbridge helps to establish the correct dosing of Gb Sciences' cannabinoid-containing Parkinson's formulations for a first-in-human trial. Dr. Robert Sutherland, Ph.D., FRSC, Professor and Chair of the Department of Neuroscience at the University of Lethbridge, Board of Governors Research Chair in Neuroscience, and Director of the Canadian Centre for Behavioral Neuroscience, used deep learning models to analyze the rich data sets from their "Home Cage Small World" behavioral assessments of rodents with video cameras and Artificial Intelligence, using a system developed by Neurocage Systems Ltd. Future studies confirming the mechanism of action of these cannabinoid-based Parkinson's formulations are planned with Dr. Sutherland's research group at the University of Lethbridge using their behavioral measurement methods for rodents.
お知らせ • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 20GB Sciences, Inc., Annual General Meeting, Mar 09, 2023GB Sciences, Inc., Annual General Meeting, Mar 09, 2023, at 10:00 Pacific Standard Time. Agenda: To consider and elect three directors to serve on Board of Directors and until each of their successors has been duly elected and qualified, unless such individuals shall sooner die, resign or be removed; to approve an amendment to articles of incorporation to increase the number of shares of stock Board of Directors is authorized to issue from 600,000,000 shares to 950,000,000 shares; to ratify the appointment of Assurance Dimensions as independent registered public accounting firm for the fiscal year ended March 31, 2023; and to transact such other business as may properly come before the Meeting or any postponement or adjournment thereof.
お知らせ • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2022, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 30Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research ArticleGb Sciences, Inc. announced that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the University of Seville in Spain have developed time-released, oral nanoparticles to deliver Gb Sciences' patent-protected chronic pain formulations, which are based on synergistic mixtures of terpenes. Terpenes are normally highly volatile, highly lipophilic molecules that are difficult to formulate into stable drug products, so Gb Sciences and their colleagues believe that nanocarriers can improve their stability, solubility, and bioavailability. In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. Concerns over those issues have made novel chronic pain treatments such as Gb Sciences' therapies an important and promising field of research and development. The Gb Sciences-sponsored study tested the effect of poly(lactide-co-glycolide) nanoparticles containing the three terpenes versus the effect of free terpenes in a cell model with TRPV1 receptors, which are known pain receptors. The study found that the encapsulated terpene nanoparticles produced significantly higher calcium responses alone or in combinations versus the free terpenes alone or in combinations. The elevated calcium responses through the TRPV1 channels indicate greater activation of these pain receptors, which can have an analgesic effect via desensitization of these important pain receptors.
お知らせ • Mar 03GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary CystitisGb Sciences, Inc. has been issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of TRPV1-receptor-associated hearing loss and urinary cystitis. Despite multiple categories of prescription heart medications on the market, heart disease remains the leading cause of death in the United States for people of most racial and ethnic groups. Alternative therapeutic approaches are still needed, especially for the treatment of advanced heart disease.
お知らせ • Jan 13An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million.An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million on December 31, 2021. The sale, valued at $8 million, will allow Gb Sciences to reduce outstanding debt and bolster its cash position. The proceeds from this sale include $1.2 million in cash, $3.8 million in immediate debt and liabilities reduction, and a $3 million interest-bearing note payable to Gb Sciences by the buyer over a three-year term. An unknown buyer completed the acquisition of Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) on December 31, 2021.
お知らせ • Sep 15GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related HyperinflammationGb Sciences, Inc. received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key anti-viral immune responses. Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August 18, 2021. The best-performing cannabinoid-containing complex mixtures will be further developed in preparation for clinical studies to evaluate their anti-inflammatory potential in the treatment of severely ill COVID-19 patients contending with Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions, such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS). CRS, MAS, and ARDS are the leading causes of death in COVID-19 patients.
お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2021, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 26GB Sciences, Inc. Announces Resignation of Leslie Bocskor as A Member of the Board of DirectorsGB Sciences, Inc. announced that effective November 23, 2020, Mr. Leslie Bocskor resigned his position as a member of the board of directors of the Company to pursue other business interests.
お知らせ • Sep 19Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX).Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017. GB Sciences did not receive any consideration in the transaction but was relieved of any obligation to fund the losses of GB Sciences Puerto Rico going forward. As the result of the transaction, GB Sciences deconsolidated the assets, liabilities and noncontrolling interests of GB Sciences Puerto Rico since its ownership interest was reduced to a non-controlling level. Cesar Cordero-Kruger completed the acquisition of an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017.
お知らせ • Aug 18GB Sciences, Inc. announced delayed 10-Q filingOn 08/17/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 14GB Sciences, Inc. announced delayed annual 10-K filingOn 08/13/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
